# Myriad Genetics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Myriad Genetics, Inc). ## Overview Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier detection across oncology, prenatal health, and mental health. The company combines laboratory testing, clinical evidence development, and commercial services to embed genetic insights into routine care. ## Products & services • Hereditary cancer testing, including MyRisk • Cancer therapy selection and HRD testing • Prenatal screening products, including Foresight and FirstGene • Pharmacogenomics testing, including GeneSight • Molecular residual disease (Precise MRD) and liquid biopsy solutions • Biopharma companion diagnostic and biomarker services - **Oncology testing** (55%) — Genetic and genomic tests for hereditary cancer risk, therapy selection, tumor profiling, and MRD. - **Prenatal health** (25%) — Non-invasive prenatal screening and carrier screening products used in pregnancy care. - **Mental health / pharmacogenomics** (15%) — GeneSight and related tests that help guide medication selection and dosing. - **Biopharma services and other** (5%) — Companion diagnostic development, biomarker services, and other precision medicine offerings. - Hereditary cancer testing, including MyRisk - Cancer therapy selection and HRD testing - Prenatal screening products, including Foresight and FirstGene - Pharmacogenomics testing, including GeneSight - Molecular residual disease (Precise MRD) and liquid biopsy solutions - Biopharma companion diagnostic and biomarker services ## Customers Myriad sells primarily to healthcare providers, including community physicians, specialists, and large health systems that order tests for their patients. It also serves patients directly through provider-ordered testing workflows, and biopharma partners that need biomarker and companion diagnostic capabilities. Demand is driven by clinical utility: buyers use the tests to improve diagnosis, personalize treatment, and support reimbursement-backed care decisions. - **Community medicine providers** (primary) — Physicians and clinics that order Myriad's tests for routine patient care because the company has broad commercial reach and EMR integration goals. - **Oncology specialists and cancer centers** (primary) — Oncologists and cancer care teams buying hereditary cancer, HRD, tumor profiling, and MRD-related tests to guide treatment and surveillance. - **Prenatal care providers** (primary) — OB/GYNs and maternal-fetal medicine practices ordering prenatal screening and carrier screening products for pregnancy risk assessment. - **Mental health prescribers** (secondary) — Psychiatrists and other prescribers using GeneSight to help select medications and improve treatment response. - **Biopharma companies** (secondary) — Drug developers buying biomarker, companion diagnostic, and regulatory support services for clinical programs. - Community physicians ordering hereditary cancer and prenatal tests - Large health systems integrating tests into clinical workflows - Oncologists using HRD, tumor profiling, and MRD-related tests - Psychiatrists and primary care clinicians using GeneSight - Biopharma partners needing biomarker and companion diagnostic services ## Geography Myriad is headquartered in the United States and generates most of its business there, with active sales operations in Japan and some international distribution. The company also had a European EndoPredict business that it sold in 2024, which reduced international exposure and simplified the portfolio. Geography matters because reimbursement, lab operations, and regulatory requirements differ by market, and the company relies on a single laboratory facility for each test. - United States is the core market for testing volume and reimbursement - Japan is an active international sales market - Certain products are distributed through international partners - European EndoPredict was divested, reducing non-U.S. exposure - Single-lab processing model increases operational concentration risk ## Strategy Myriad's strategy is to accelerate profitable growth by deepening its position in cancer care, expanding prenatal health, and improving mental health reimbursement and account penetration. It is also investing in automation, EMR integration, clinical evidence, and partnerships such as PATHOMIQ and SOPHiA Genetics to broaden the portfolio faster than internal development alone would allow. - **Grow oncology across the Cancer Care Continuum** (medium-term) — Oncology is the largest strategic opportunity and supports cross-selling across hereditary cancer, therapy selection, and MRD. - **Scale prenatal and mental health franchises** (short-term) — These businesses provide recurring demand and can offset pressure in pharmacogenomics reimbursement. - **Improve operating leverage and profitability** (medium-term) — Automation and standardized processes are intended to lower cost per test and reduce operating expenses as a share of revenue. - Expand the Cancer Care Continuum portfolio, especially high-growth applications - Grow Prenatal Health and Mental Health at or above market growth - Build MRD and liquid biopsy capabilities through product development and partnerships - Increase EMR integration and large health system adoption - Improve lab automation, turnaround time, and cost efficiency ## Risks Myriad faces reimbursement pressure, especially in pharmacogenomics, where UnitedHealthcare coverage changes have already reduced revenue. The business is also exposed to cybersecurity, third-party lab and phlebotomy dependencies, supply chain disruption, and concentration in single-lab processing, while competition and rapid technology change can erode pricing and adoption. - **Reimbursement and coverage risk** [high] — Test demand depends on payer coverage; UnitedHealthcare's GeneSight change already hurt pharmacogenomics revenue. - **Cybersecurity and data privacy risk** [high] — The company handles sensitive genetic and health data, so breaches could cause financial, regulatory, and reputational damage. - **Third-party specimen collection dependency** [medium] — Some tests rely on external labs and phlebotomy clinics; loss of access could prevent testing and delay revenue. - **Single-laboratory operational concentration** [high] — Each test is processed in one laboratory facility, so an outage or compliance issue could seriously harm operations. - **Competitive and technological disruption** [medium] — The diagnostics market has frequent product launches, price competition, and changing standards that can pressure share and margins. - Insurance coverage changes can quickly reduce test utilization and pricing - Cybersecurity or IT outages could disrupt sensitive patient data and operations - Third-party labs and phlebotomy clinics are critical for specimen collection - Single-lab processing creates concentration risk if a facility is interrupted - Competition and reimbursement pressure can limit commercialization and margins ## Accounting Revenue is driven by test volume and average revenue per test, so payer mix, coverage changes, and timing of recognition can materially affect quarterly results. Investors should also watch goodwill and intangible asset impairment, because the company recorded large impairment charges in 2025 after a sustained market-cap decline and forecast revisions, and these non-cash charges can significantly distort reported earnings. - **Revenue recognition for diagnostic tests** — Can create quarter-to-quarter volatility in reported sales - **Goodwill and intangible asset impairment** — Can materially reduce earnings and book value - **Valuation allowance on deferred tax assets** — Affects tax expense and effective tax rate - **Cost of revenue and lab efficiency** — Impacts gross margin and operating leverage - Revenue depends on test volume, payer mix, and average revenue per test - Coverage changes can shift timing and amount of recognized revenue - Goodwill and intangible assets are sensitive to forecast revisions and market cap - Impairment charges can create large non-cash losses in a quarter - Cost per test is affected by lab reagent and supply costs --- *Last updated: 2026-04-28T20:25:56.838721+00:00*